Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
Hamid O, Hassel JC, Shoushtari AN, Meier F, Bauer TM, Salama AKS, Kirkwood JM, Ascierto PA, Lorigan PC, Mauch C, Orloff M, Evans TRJ, Holland C, Edukulla R, Abedin SE, Middleton MR.
Hamid O, et al. Among authors: edukulla r.
J Immunother Cancer. 2023 Jun;11(6):e006747. doi: 10.1136/jitc-2023-006747.
J Immunother Cancer. 2023.
PMID: 37286303
Free PMC article.
Clinical Trial.